DOBI Medical names new engineering VP
Dr. Lim Cheung has joined DOBI Medical Systems to advance the company's Dynamic Optical Breast Imaging system after spending six years at Trex Medical, where he developed that company's digital mammography unit.Cheung took over last month as the New
Dr. Lim Cheung has joined DOBI Medical Systems to advance the company's Dynamic Optical Breast Imaging system after spending six years at Trex Medical, where he developed that company's digital mammography unit.
Cheung took over last month as the New Jersey-based company's vice president of engineering. Before working for Trex Medical, he was head of the optical physics department at Grumann Aerospace.
While at Trex, Cheung was vice president of research and development. Trex's digital mammography system was in the running to be the first of its kind to go to market in the U.S., but the FDA rejected Trex's 510(k) and instead cleared GE Medical's premarket approval application (SCAN 2/16/00). Trex officials said this spring that the company is going through the PMA process for its full-field digital mammography unit (SCAN 4/26/00).
Cheung said digital mammography and DOBI's optical breast imaging system have some things in common.
"It is very closely related because in digital mammography we use x-ray optics to image," he said. "The technique I am working on now is intended (for) diagnostic purposes to be able to discriminate between benign and malignant lesions."
The DOBI system will be used initially as an adjunct to traditional mammography. It operates by detecting the effects of increased vascularization (angiogenesis) associated with the growth of malignant lesions (SCAN 5/24/00). Cheung said DOBI will submit a PMA for the system sometime next year.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
